MX2019014934A - Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. - Google Patents

Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.

Info

Publication number
MX2019014934A
MX2019014934A MX2019014934A MX2019014934A MX2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A
Authority
MX
Mexico
Prior art keywords
methods
combination therapy
brain tumors
treating brain
treating
Prior art date
Application number
MX2019014934A
Other languages
English (en)
Inventor
David Schenkein
Nelamangala Nagaraja
Joshua Murtie
Brandon Nicolay
Katharine Yen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2019014934A publication Critical patent/MX2019014934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan métodos para tratar un tumor cerebral en un paciente que lo necesita que comprende administrar al paciente un compuesto descrito en la presente descripción y una terapia de radiación y/o uno o más agentes terapéuticos adicionales.
MX2019014934A 2017-06-12 2018-06-12 Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. MX2019014934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518565P 2017-06-12 2017-06-12
PCT/US2018/037062 WO2018231796A1 (en) 2017-06-12 2018-06-12 Methods of treating brain tumors using combination therapy

Publications (1)

Publication Number Publication Date
MX2019014934A true MX2019014934A (es) 2022-06-28

Family

ID=62815154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014934A MX2019014934A (es) 2017-06-12 2018-06-12 Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.

Country Status (11)

Country Link
US (3) US10780093B2 (es)
EP (1) EP3638245A1 (es)
JP (3) JP7263669B2 (es)
KR (1) KR20200015745A (es)
CN (1) CN111182905A (es)
BR (1) BR112019026378A2 (es)
CA (1) CA3067028A1 (es)
IL (1) IL271307A (es)
MX (1) MX2019014934A (es)
TW (1) TWI830700B (es)
WO (1) WO2018231796A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
WO2010105243A1 (en) * 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) * 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CA2838973A1 (en) * 2011-06-17 2012-12-20 Adrian L. Harris Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US9579324B2 (en) * 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2016288246A1 (en) * 2015-07-02 2018-02-01 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
WO2017066566A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc Combination therapy for treating malignancies
MX2018004599A (es) * 2015-10-15 2018-09-21 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.

Also Published As

Publication number Publication date
CN111182905A (zh) 2020-05-19
JP2023025277A (ja) 2023-02-21
JP7263669B2 (ja) 2023-04-25
AU2018284101A1 (en) 2019-12-19
JP2020523412A (ja) 2020-08-06
US20210046081A1 (en) 2021-02-18
BR112019026378A2 (pt) 2020-07-21
EP3638245A1 (en) 2020-04-22
US20220362250A1 (en) 2022-11-17
TW201902484A (zh) 2019-01-16
TWI830700B (zh) 2024-02-01
CA3067028A1 (en) 2018-12-20
JP2023025276A (ja) 2023-02-21
KR20200015745A (ko) 2020-02-12
US20180353514A1 (en) 2018-12-13
WO2018231796A1 (en) 2018-12-20
US10780093B2 (en) 2020-09-22
IL271307A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
SG10201902664RA (en) Combination therapy for treating cancer
WO2016043874A3 (en) Combination therapy for treating cancer
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020001727A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2019003751A (es) Proteina terapeutica.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.